Ursodiol - PharmaKB

Ursodiol

Actigall, Urso, Ursodiol (ursodiol) is a small molecule pharmaceutical. Ursodiol was first approved as Actigall on 1987-12-31. It is used to treat biliary liver cirrhosis and cholelithiasis in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
digestive system diseases	D004066
signs and symptoms pathological conditions	D013568

Trade Name

FDA

EMA

Actigall, Urso, Ursodiol (discontinued: Actigall, Ursodiol)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Ursodiol

Tradename	Company	Number	Date	Products
URSO 250	Allergan	N-020675 RX	1997-12-10	1 products, RLD
URSO FORTE	Allergan	N-020675 RX	2004-07-21	1 products, RLD, RS
ACTIGALL	Teva	N-019594 RX	1987-12-31	1 products, RLD, RS

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
festal plus	unapproved drug other	2018-11-22
reltone 200 mg reltone 400 mg	ANDA	2023-01-16
urso 250 urso forte	New Drug Application	2023-01-12
urso urso forte		2008-05-27
ursodiol	ANDA	2024-12-19
ursodiol 200 mg ursodiol 400 mg	ANDA	2024-11-26
ursodiol capsules	ANDA	2010-05-25
urusa	unapproved drug other	2018-11-19

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
biliary liver cirrhosis	—	D008105	K74.3
cholelithiasis	EFO_0004799	D002769	K80

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

A: Alimentary tract and metabolism drugs

— A05: Bile and liver therapy drugs

— A05A: Bile therapy drugs

— A05AA: Bile acids and derivatives for bile therapy

— A05AA02: Ursodeoxycholic acid

HCPCS

No data

Clinical

Clinical Trials

191 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Biliary liver cirrhosis	D008105	—	K74.3	3	25	29	7	8	67
Cholangitis	D002761	HP_0030151	K83.0	4	17	17	5	8	45
Fibrosis	D005355	—	—	4	14	11	2	5	34
Liver cirrhosis	D008103	EFO_0001422	K74.0	5	12	11	2	3	31
Liver diseases	D008107	HP_0002910	K70-K77	2	7	1	1	4	13
Diabetes mellitus	D003920	HP_0000819	E08-E13	—	4	7	2	1	12
Type 2 diabetes mellitus	D003924	EFO_0001360	E11	—	3	5	2	1	10
Hepatitis	D006505	HP_0012115	K75.9	—	3	2	3	2	9
Gallstones	D042882	EFO_0004210	—	—	—	2	4	3	9
Non-alcoholic fatty liver disease	D065626	EFO_0003095	K75.81	—	2	—	2	3	7

Show 27 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Cholestasis	D002779	HP_0001396	K83.1	—	6	6	—	4	14
Healthy volunteers/patients	—	—	—	6	—	1	—	1	8
Sclerosing cholangitis	D015209	EFO_0004268	K83.01	3	3	2	—	1	7
Intrahepatic cholestasis	D002780	—	—	—	3	3	—	1	6
Colorectal neoplasms	D015179	—	—	1	4	2	—	—	5
Pregnancy complications	D011248	—	—	—	1	2	—	1	3
Glucose intolerance	D018149	HP_0000833	R73.03	1	1	1	—	1	3
Malnutrition	D044342	EFO_0008572	E40-E46	2	1	1	—	—	3
Neoplasms	D009369	—	C80	—	1	1	—	1	2
Adenomatous polyposis coli	D011125	—	D13.91	—	2	2	—	—	2

Show 17 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Covid-19	D000086382	—	—	1	2	—	—	3	5
Gastrointestinal diseases	D005767	—	—	1	3	—	—	—	3
Digestive system diseases	D004066	HP_0011024	K92.9	1	3	—	—	—	3
Cardiomyopathies	D009202	EFO_0000318	I42	—	1	—	—	1	2
Disease progression	D018450	—	—	—	1	—	—	1	2
Amyloidosis	D000686	EFO_1001875	E85	—	1	—	—	1	2
Chronic chemical and drug induced liver injury	D056487	EFO_1000905	—	2	2	—	—	—	2
Rheumatoid arthritis	D001172	EFO_0000685	M06.9	—	2	—	—	—	2
Arthritis	D001168	HP_0001369	M05-M14	—	2	—	—	—	2
Biliary tract diseases	D001660	EFO_0009534	K83.9	1	2	—	—	—	2

Show 28 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Overweight	D050177	—	E66.3	1	—	—	—	—	1
Liver function tests	D008111	—	—	1	—	—	—	—	1
Gastric bypass	D015390	EFO_0005244	—	1	—	—	—	—	1
Aging	D000375	GO_0007568	R41.81	1	—	—	—	—	1
Huntington disease	D006816	Orphanet_399	G10	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Infections	D007239	EFO_0000544	—	—	—	—	—	2	2
Communicable diseases	D003141	—	—	—	—	—	—	2	2
Peroxisomal disorders	D018901	Orphanet_44	E71.5	—	—	—	—	1	1
Zellweger syndrome	D015211	Orphanet_912	E71.510	—	—	—	—	1	1
Infantile refsum disease	D052919	Orphanet_772	G60.1	—	—	—	—	1	1
Adrenoleukodystrophy	D000326	Orphanet_43	E71.52	—	—	—	—	1	1
Refsum disease	D012035	Orphanet_773	G60.1	—	—	—	—	1	1
Immunoglobulin light-chain amyloidosis	D000075363	—	—	—	—	—	—	1	1
Familial amyloid neuropathies	D028227	—	E85.1	—	—	—	—	1	1
Amyloid neuropathies	D017772	—	—	—	—	—	—	1	1

Show 32 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Ursodiol
INN	ursodeoxycholic acid
Description	Ursodeoxycholic acid is a bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. It has a role as a human metabolite and a mouse metabolite. It is a bile acid, a dihydroxy-5beta-cholanic acid and a C24-steroid. It is a conjugate acid of an ursodeoxycholate.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C